Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study
- PMID: 26109206
- DOI: 10.1182/blood-2015-04-639336
Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study
Abstract
The optimal combination and sequence of radiotherapy (RT) and chemotherapy (CT) for extranodal nasal-type natural killer/T-cell lymphoma (NKTCL) are not well-defined. The aim of this study was to create a risk-adapted therapeutic strategy for early-stage NKTCL. A total of 1273 early-stage patients from 10 institutions were reviewed. Patients received CT alone (n = 170), RT alone (n = 253), RT followed by CT (n = 209), or CT followed by RT (n = 641). A comprehensive comparative study was performed using multivariable and propensity score-matched analyses. Early-stage NKTCL was classified as low risk or high risk based on 5 independent prognostic factors (stage, age, performance status, lactate dehydrogenase, primary tumor invasion). RT alone and RT with or without CT were more effective than CT alone (5-year overall survival [OS], 69.6% and 67.7% vs 33.9%, P < .001). For low-risk patients, RT alone achieved a favorable OS (88.8%); incorporation of induction or consolidation CT did not provide additional benefit (86.9% and 86.3%). For high-risk patients, RT followed by CT resulted in superior OS (72.2%) compared with induction CT and RT (58.3%, P = .004) or RT alone (59.6%, P = .017). After adjustment, similar significant differences in OS were still observed between treatment groups. New CT regimens provided limited benefit in early-stage NKTCL. Risk-adapted therapy involving RT alone for low-risk patients and RT consolidated by CT for high-risk patients is a viable, effective strategy for early-stage NKTCL.
© 2015 by The American Society of Hematology.
Comment in
-
Nasal NK/T-cell lymphoma: RT, CT, or both.Blood. 2015 Sep 17;126(12):1400-1. doi: 10.1182/blood-2015-07-655191. Blood. 2015. PMID: 26384281
Similar articles
-
Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma.JAMA Oncol. 2017 Jan 1;3(1):83-91. doi: 10.1001/jamaoncol.2016.5094. JAMA Oncol. 2017. PMID: 27893001
-
[Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma].Zhonghua Zhong Liu Za Zhi. 2019 Nov 23;41(11):859-864. doi: 10.3760/cma.j.issn.0253-3766.2019.11.011. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31770855 Chinese.
-
Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG).Radiother Oncol. 2018 Oct;129(1):3-9. doi: 10.1016/j.radonc.2018.04.026. Epub 2018 May 5. Radiother Oncol. 2018. PMID: 29739712
-
Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study.Am J Hematol. 2020 Sep;95(9):1047-1056. doi: 10.1002/ajh.25878. Epub 2020 Jul 16. Am J Hematol. 2020. PMID: 32449800 Clinical Trial.
-
The optimal timing of radiotherapy in the combined modality therapy for limited-stage extranodal NK/T cell lymphoma (ENKTL): a systematic review and meta-analysis.Ann Hematol. 2018 Dec;97(12):2279-2287. doi: 10.1007/s00277-018-3479-2. Epub 2018 Aug 20. Ann Hematol. 2018. PMID: 30128904 Review.
Cited by 54 articles
-
How we treat NK/T-cell lymphomas.J Hematol Oncol. 2022 Jun 3;15(1):74. doi: 10.1186/s13045-022-01293-5. J Hematol Oncol. 2022. PMID: 35659326 Free PMC article. Review.
-
A Prospective Phase II Study of Pegaspargase-COEP Plus Radiotherapy in Patients With Newly Diagnosed Extra-Nodal NK/T-Cell Lymphoma.Front Oncol. 2022 Feb 25;12:839252. doi: 10.3389/fonc.2022.839252. eCollection 2022. Front Oncol. 2022. PMID: 35280751 Free PMC article.
-
Progress of Hematopoietic Stem Cell Transplantation and Radiotherapy in the Treatment of Extranodal NK/T Cell Lymphoma.Front Oncol. 2022 Feb 16;12:832428. doi: 10.3389/fonc.2022.832428. eCollection 2022. Front Oncol. 2022. PMID: 35252002 Free PMC article. Review.
-
Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine.Diagnostics (Basel). 2022 Feb 5;12(2):409. doi: 10.3390/diagnostics12020409. Diagnostics (Basel). 2022. PMID: 35204500 Free PMC article. Review.
-
Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies.Cancers (Basel). 2022 Jan 25;14(3):597. doi: 10.3390/cancers14030597. Cancers (Basel). 2022. PMID: 35158865 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
